Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Chinese University of Hong Kong Hoffmann-La Roche |
---|---|
Information provided by: | Chinese University of Hong Kong |
ClinicalTrials.gov Identifier: | NCT00226382 |
This study is to investigate the HBV DNA suppression (and HBeAg seroconversion among HBeAg positive patients) pegylated interferon treatment at 24 weeks after end of treatment among patients who have failed anti-viral treatment in the past.
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis B |
Drug: Pegylated Interferon-alfa-2a |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Treatment With Peginterferon Alfa-2a (40 KD) (PEGASYS®) of Chronic Hepatitis B Patients, Who Have Failed Anti-Viral Treatment. A Pilot Study. |
Estimated Enrollment: | 49 |
Study Start Date: | January 2005 |
Chronic hepatitis B is the commonest cause of liver cirrhosis and hepatocellular carcinoma in Hong Kong.
Persistent high viraemia and necro-inflammation is associated with higher risk of liver-related complications.
Lamivudine and adefovir dipivoxil are the two anti-viral agents that can suppress the replication of the virus.
However, these drugs using either alone or in combination only induce HBeAg seroconversion in less than 20% of patients. Most patients therefore required long-term treatment, which has a risk of development of drug resistance. Premature cessation of these anti-viral agents is usually accompanied by relapse of viraemia and hepatitis.
Pegylated interferon-alfa-2a is modified form of interferon with a 40 kDa polyethylene glycol strand attached to a recombinant interferon. This formulation increases the product’s half-life from 7-10 hours to 77 hours.
Therefore it can be administered on a more convenient once weekly basis. Pegylated interferon-alfa-2a monotherapy for 24 weeks has been shown to induce sustained HBeAg seroconversion in 35% of patients at the optimal dose of 180 mcg weekly. This drug has been found to be more effective than conventional interferon-alfa in the treatment of chronic hepatitis B as well as chronic hepatitis C.
Data on interferon-based treatment among chronic hepatitis B patients who have failed previous anti-viral treatment is scanty. It is uncertain whether pegylated interferon-alfa-2a treatment will be effective in this group of patients. This is a single-center, pilot study on the virological response of chronic HBV infection to pegylated interferon-alfa-2a among patients who have failed anti-viral treatment in the past. This study will investigate the HBV DNA suppression (and HBeAg seroconversion among HBeAg positive patients) pegylated interferon treatment at 24 weeks after end of treatment.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Henry LY Chan, MD | (852)2632-2211 | hlychan@cuhk.edu.hk |
Contact: Angel ML Chim, MScEPB | (852)2632-4205 | angelchim@cuhk.edu.hk |
China | |
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital | Recruiting |
Hong Kong SAR, China | |
Contact: Henry LY Chan, MD (852)2632-2211 hlychan@cuhk.edu.hk | |
Contact: Angel ML Chim, MScEPB (852)2632-4205 angelchim@cuhk.edu.hk | |
Sub-Investigator: Alex Y Hui, MBBChir | |
Sub-Investigator: Vincent WS Wong, MBChB | |
Sub-Investigator: Joseph JY Sung, MD, PhD |
Principal Investigator: | Henry LY Chan, MD | Chinese University of Hong Kong |
Study ID Numbers: | Pegasys Study |
Study First Received: | September 23, 2005 |
Last Updated: | October 27, 2006 |
ClinicalTrials.gov Identifier: | NCT00226382 History of Changes |
Health Authority: | Hong Kong: Department of Health |
Chronic Hepatitis B Pegylated Interferon-alfa-2a Pegasys |
Interferon-alpha Anti-Infective Agents Liver Diseases Immunologic Factors Hepatitis, Chronic Interferons Hepatitis, Viral, Human Angiogenesis Inhibitors Antiviral Agents |
Hepatitis Virus Diseases Digestive System Diseases Hepatitis B, Chronic Hepatitis B Peginterferon alfa-2a DNA Virus Infections Interferon Alfa-2a |
Anti-Infective Agents Liver Diseases Hepatitis, Chronic Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Hepatitis, Viral, Human Hepadnaviridae Infections Hepatitis B, Chronic Therapeutic Uses Hepatitis B Angiogenesis Modulating Agents Growth Inhibitors |
Interferon-alpha Growth Substances Interferons Antiviral Agents Angiogenesis Inhibitors Pharmacologic Actions Virus Diseases Hepatitis Digestive System Diseases Peginterferon alfa-2a DNA Virus Infections Interferon Alfa-2a |